Maison_Hardin Posted - 1 day ago

🚨 MYNZ Petra Brand Ambassador says to keep an eye on "BIG NEWS from the NFL." This is going to run parabolic soon, right after the healthcare giant Thermo Fisher ($210B mkt cap) partnered with Mainz to develop and launch together ColoAlert in US 🚀 Buy the dip now, the train is leaving very soon. $CORT $CRNX $BHVN

Logan_Jackson Posted - 3 days ago

$CRNX $BHVN LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

Sullkid Posted - 5 days ago

$BHVN they filling the gap here?

Sergecker Posted - 1 week ago

$BHVN $RARE 😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic.

TheKB1 Posted - 1 week ago

$BHVN looks like a wild over reaction to RFK Jr appointment. Buy up at this price

Nosh Posted - 1 week ago

$BHVN Small starter....almost all my BIOs hit buy ranges.

TheKB1 Posted - 1 week ago

$BHVN buy the dip

Article_AI Posted - 1 week ago

$BHVN Biohaven Ltd. (BHVN) Receives a Buy from Morgan Stanley In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price targe... https://www.stck.pro/news/BHVN/93189490/

fazul Posted - 1 week ago

$BHVN Phase 3 Resiliant study SMA results taking forever to be released....somebody get a whiff of bad news?

moneybags4ever Posted - 1 week ago

$BHVN can someone explain this?

bioanticipation Posted - 1 week ago

$BHVN halfway there

Article_AI Posted - 1 week ago

$BHVN Biohaven Ltd.: Strong Buy Rating Driven by Promising Pipeline Progress and Strategic Resubmissions Analyst Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $60.00... https://www.stck.pro/news/BHVN/93109256/

Thestocktraderhubzee Posted - 1 week ago

WATCHLIST NOV 14 2024.. $OBIO Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target $GOVX D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target $BHVN TD Cowen Maintains Buy on Biohaven, Raises Price Target to $75 $ATEN BWS Financial Maintains Buy on A10 Networks, Raises Price Target to $24 $EVH Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $21

swingingtech Posted - 1 week ago

$PANW $BHVN $JACK https://wallstreetwaves.com/key-wednesday-options-highlights-panw-bhvn-jack/

DoctorEmmettBrown Posted - 1 week ago

$BHVN Dr. (just like me) Vlad Coric’s track record of success in the biopharmaceutical industry makes him a leader who shouldn’t be bet against. Under his guidance biohaven developed and brought Nurtec ODT to market, which revolutionized migraine treatment and became a top prescribed drug in its category. This achievement positioned Biohaven as a key player in neurology and led to its $11.6 billion acquisition by Pfizer, solidifying Coric’s reputation for creating shareholder value. post-acquisition, Coric launched Biohaven LTD demonstrating his ability to pivot & build from the ground up while maintaining a focus on unmet medical needs. The company has since developed a diversified and innovative pipeline, with troriluzole leading the charge as a potential first-to-market treatment for Spinocerebellar Ataxia. His ability to secure orphan drug, fast-track, and priority review designations highlights his understanding of regulatory pathways, ensuring Biohaven remains a step ahead.

DoctorEmmettBrown Posted - 1 week ago

$BHVN I cannot recall the last time I saw the most perfect cup and handle

Quantumup Posted - 1 week ago

TD Cowen⬆️PT $BHVN $75 was $55/Buy, on upcoming🐈s—says R/R is favorable for Ph3🔬for T-alfa in SMA, due any day; NDA in SCA;+4: RBC Capital⬇️PT $BHVN $66 was $68/OP. For Upcoming🐈s : ✪ sees 30%⬆️on +VE SMA🔬 ✪ sees 20%⬆️on +VE IgG degrader🔬 ✪ remains very🐂on Kv7 program:

DoctorEmmettBrown Posted - 1 week ago

$BHVN A Trump administration is likely bullish for Biohaven due to faster FDA approvals, tax benefits, IP protections, and biomanufacturing support. Risks include drug pricing reforms and healthcare policy shifts, but orphan drug focus and innovation make Biohaven well-positioned overall.

IN0V8 Posted - 1 week ago

$BHVN Watching RBC cuts target price to $66 from $68 TD Cowen raises target price to $75 from $55 Craig-Hallum raises target price to $32 from $30 Jefferies raises target price to $30 from $26 TD Cowen raises target price to $31 from $28

DoctorEmmettBrown Posted - 1 week ago

$BHVN The NDA submission for troriluzole in Spinocerebellar Ataxia (SCA) is likely Biohaven’s most bullish event in Q4 2024, even among other milestones. It reflects confidence in their pivotal trial data, which showed significant efficacy, slowed disease progression by 50-70%, and met all primary and secondary endpoints. The alignment with the FDA on study design and analysis reduces regulatory risk and demonstrates the quality of the submission. Troriluzole has the potential to be the first FDA-approved treatment for SCA, addressing a debilitating disease with no current therapies. This breakthrough not only meets a critical unmet need but also positions the drug for orphan pricing and fast-track priority review, potentially accelerating approval and market entry. While SMA and migraine trials are important, the SCA submission is closer to commercialization and revenue generation, making it a near-term driver.

DonCorleone77 Posted - 1 week ago

$BHVN Biohaven reports Q3 adjusted EPS ($1.74), consensus ($1.70) Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "The team at Biohaven continues to advance multiple late and early stage assets that have the potential to change the current standard of care treatment paradigm across a number of diseases. Last quarter we announced positive topline results in our RWE trial assessing troriluzole for the treatment of spinocerebellar ataxia. Troriluzole (200 mg dosed orally) met the study's primary endpoint on the change from baseline in the f-SARA at 3 years in all study population genotypes, showed statistically significant superiority after both 1 and 2 years of treatment, and achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints. This was truly a watershed moment for the Company, given the implications of potentially bending the arc of one of the most intractable neurological diseases with no currently approved treatment options. SCA robs patients of their ability to speak, walk, and take care of themselves, and often shortens lifespans and has unfortunate intergenerational implications. We were encouraged by the robust dataset gathered to date and look forward to submitting an NDA to the FDA."

OnlyEverLong Posted - 1 week ago

@BioLong123 thought we'd see them premarket today. It was listed as such on my brokerage app and several other places. But searching around a bit this morning, I see other dates listed, most commonly the 19th and 26th. This has happened before with $BHVN. They likely didn't release an official date and assumptions are made from historical trends- somewhat frustrating as an investor. Numbers matter less than the news, which could be released anytime, though. At minimum earnings release would have updates on progress which likely will be received poorly if nothing's new.

BioLong123 Posted - 1 week ago

$BHVN anyone know when earnings are out?

Buylowfordoe Posted - 1 week ago

$BHVN is no news good news?

DonCorleone77 Posted - 1 week ago

$BHVN Biohaven options imply 19.6% move in share price post-earnings Pre-earnings options volume in Biohaven is normal with calls leading puts 8:7. Implied volatility suggests the market is anticipating a move near 19.6%, or $10.27, after results are released. Median move over the past eight quarters is 4.1%.

JuggernautRaider Posted - 1 week ago

Look me up on Linkedin bro. I used to work at $BMY . I have forgotten more about biopharma than you have learned in my 15 year career in New Jersey. $BHVN, $GILD PPBT, $RDHL, $TLSA are gems. Give me three better picks. I will wait.

JuggernautRaider Posted - 1 week ago

Both of what? You should own $BHVN or $AXSM . Avoid $SAGE until their CEO quits the board of $KPTI

GreenElite Posted - 1 week ago

$BHVN price target?

StockConsultant Posted - 1 week ago

$BHVN Biohaven stock, nice trend, watch for a narrow range breakout, earnings 11/12 pMkt at https://stockconsultant.com/?BHVN

traderhr Posted - 1 week ago

📊 Free Stock Watch List for Nov 11th! $AJG $BHVN $FFWM 👉 View the full list: https://www.traderhr.com/free-watch-list-for-nov-11th-2024/